Home LiteratureArticle Details
PMID: 18638373 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays.

Breast cancer research : BCR ·Vol. 10 ·No. 4 ·2008-00-00 ·Pages R62

Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, Tuck AB, Chambers AF

Abstract

Breast cancer metastasis is a complex, multi-step biological process. Genetic mutations along with epigenetic alterations in the form of DNA methylation patterns and histone modifications contribute to metastasis-related gene expression changes and genomic instability. So far, these epigenetic contributions to breast cancer metastasis have not been well characterized, and there is only a limited understanding of the functional mechanisms affected by such epigenetic alterations. Furthermore, no genome-wide assessments have been undertaken to identify altered DNA methylation patterns in the context of metastasis and their effects on specific functional pathways or gene networks. We have used a human gene promoter tiling microarray platform to analyze a cell line model of metastasis to lymph nodes composed of a poorly metastatic MDA-MB-468GFP human breast adenocarcinoma cell line and its highly metastatic variant (468LN). Gene networks and pathways associated with metastasis were identified, and target genes associated with epithelial-mesenchymal transition were validated with respect to DNA methylation effects on gene expression. We integrated data from the tiling microarrays with targets identified by Ingenuity Pathways Analysis software and observed epigenetic variations in genes implicated in epithelial-mesenchymal transition and with tumor cell migration. We identified widespread genomic hypermethylation and hypomethylation events in these cells and we confirmed functional associations between methylation status and expression of the CDH1, CST6, EGFR, SNAI2 and ZEB2 genes by quantitative real-time PCR. Our data also suggest that the complex genomic reorganization present in cancer cells may be superimposed over promoter-specific methylation events that are responsible for gene-specific expression changes. This is the first whole-genome approach to identify genome-wide and gene-specific epigenetic alterations, and the functional consequences of these changes, in the context of breast cancer metastasis to lymph nodes. This approach allows the development of epigenetic signatures of metastasis to be used concurrently with genomic signatures to improve mapping of the evolving molecular landscape of metastasis and to permit translational approaches to target epigenetically regulated molecular pathways related to metastatic progression.

MeSH Terms
Breast Neoplasms/diagnosis,genetics,metabolism Cell Line, Tumor DNA Methylation Epigenesis, Genetic Gene Expression Regulation, Neoplastic Genome Histones/metabolism Humans Lymph Nodes/pathology Models, Genetic Neoplasm Metastasis Oligonucleotide Array Sequence Analysis Prognosis Promoter Regions, Genetic Reverse Transcriptase Polymerase Chain Reaction
Chemicals
Histones
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Rodenhiser David I
London Regional Cancer Program, Victoria Research Laboratories, London Health Sciences Centre, 790 Commissioners Road East, London, Ontario, N6A 4L6, Canada. drodenhi@uwo.ca
Andrews Joseph
Kennette Wendy
Sadikovic Bekim
Mendlowitz Ariel
Tuck Alan B
Chambers Ann F
References (57)
57 references, click to expand
  1. Genes that mediate breast cancer metastasis to lung.
    Nature. 2005 Jul 28;436(7050):518-24 PMID: 16049480
  2. Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer.
    Cancer Lett. 2005 Jun 1;223(1):143-50 PMID: 15890247
  3. Exploration, normalization, and summaries of high density oligonucleotide array probe level data.
    Biostatistics. 2003 Apr;4(2):249-64 PMID: 12925520
  4. Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis.
    Cancer Genet Cytogenet. 2008 Feb;181(1):1-7 PMID: 18262045
  5. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Clin Cancer Res. 2005 Feb 15;11(4):1380-5 PMID: 15746036
  6. A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes.
    Clin Exp Metastasis. 2005;22(4):351-61 PMID: 16170671
  7. Identification of molecular markers for metastasis-related genes in primary breast cancer cells.
    Clin Exp Metastasis. 2005;22(1):59-67 PMID: 16132579
  8. DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma.
    Biomed Pharmacother. 2005 Oct;59 Suppl 2:S363-5 PMID: 16507410
  9. Dissecting the metastatic cascade.
    Nat Rev Cancer. 2004 Jun;4(6):448-56 PMID: 15170447
  10. Epigenetics and human disease: translating basic biology into clinical applications.
    CMAJ. 2006 Jan 31;174(3):341-8 PMID: 16446478
  11. Chromatin modifications and their function.
    Cell. 2007 Feb 23;128(4):693-705 PMID: 17320507
  12. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex.
    J Biol Chem. 2007 Nov 23;282(47):34448-56 PMID: 17878164
  13. Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors.
    Cancer Genet Cytogenet. 2003 Oct 1;146(1):33-40 PMID: 14499694
  14. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors).
    Mod Pathol. 2007 Jul;20(7):802-10 PMID: 17483816
  15. Analysis of a multifactor microarray study using Partek genomics solution.
    Methods Enzymol. 2006;411:256-70 PMID: 16939794
  16. Inverse correlation between the expression of O6-methylguanine-DNA methyl transferase (MGMT) and p53 in breast cancer.
    Jpn J Clin Oncol. 2005 Mar;35(3):121-5 PMID: 15741301
  17. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
    Cancer Res. 2007 Dec 15;67(24):11517-27 PMID: 18089780
  18. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
    Nat Rev Cancer. 2007 Jun;7(6):415-28 PMID: 17508028
  19. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.
    Cancer Res. 2005 Jul 1;65(13):5578-87 PMID: 15994930
  20. Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.
    Cancer Biol Ther. 2006 Nov;5(11):1494-501 PMID: 17369752
  21. Studies on the methylation status of CpG sequences located in promoters of selected tumour suppressor genes in breast cancer cells.
    Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1025-8 PMID: 17065058
  22. MethPrimer: designing primers for methylation PCRs.
    Bioinformatics. 2002 Nov;18(11):1427-31 PMID: 12424112
  23. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    J Cell Physiol. 2007 Aug;212(2):330-44 PMID: 17458893
  24. Epigenetic contributions to cancer metastasis.
    Clin Exp Metastasis. 2009;26(1):5-18 PMID: 18386135
  25. CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.
    BMC Cancer. 2006 Mar 02;6:48 PMID: 16512896
  26. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
    Nat Rev Cancer. 2003 Jun;3(6):453-8 PMID: 12778135
  27. Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.
    J Cancer Res Clin Oncol. 2005 Mar;131(3):191-8 PMID: 15592684
  28. Multiple sequence alignment with the Clustal series of programs.
    Nucleic Acids Res. 2003 Jul 1;31(13):3497-500 PMID: 12824352
  29. CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells.
    PLoS Genet. 2007 Sep;3(9):1757-69 PMID: 17907813
  30. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
    Oncogene. 2005 Jul 7;24(29):4721-7 PMID: 15897910
  31. Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.
    BMC Mol Biol. 2007 Dec 03;8:110 PMID: 18053161
  32. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  33. Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
    Exp Mol Pathol. 2007 Oct;83(2):188-97 PMID: 17540367
  34. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
    Cancer Res. 2003 Feb 1;63(3):664-73 PMID: 12566312
  35. Epigenetic silencing of CXCL12 increases the metastatic potential of mammary carcinoma cells.
    Oncogene. 2008 Feb 28;27(10):1461-71 PMID: 17724466
  36. Loss of epigenetic control of synuclein-gamma gene as a molecular indicator of metastasis in a wide range of human cancers.
    Cancer Res. 2005 Sep 1;65(17):7635-43 PMID: 16140929
  37. Tumor-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implications.
    Oncol Rep. 2003 Nov-Dec;10(6):1811-5 PMID: 14534701
  38. Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis.
    Clin Exp Metastasis. 2007;24(8):575-85 PMID: 17973194
  39. The epithelial-mesenchymal transition: new insights in signaling, development, and disease.
    J Cell Biol. 2006 Mar 27;172(7):973-81 PMID: 16567498
  40. Of mice and Myc: c-Myc and mammary tumorigenesis.
    J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):27-37 PMID: 15082916
  41. The mammalian epigenome.
    Cell. 2007 Feb 23;128(4):669-81 PMID: 17320505
  42. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Breast Cancer Res Treat. 2008 Oct;111(3):429-37 PMID: 17965955
  43. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis.
    Clin Cancer Res. 2005 Mar 15;11(6):2156-62 PMID: 15788661
  44. DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
    Lab Invest. 2006 Dec;86(12):1233-42 PMID: 17043665
  45. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients.
    Breast Cancer Res Treat. 2007 Jul;103(3):319-29 PMID: 17123152
  46. A multigenic program mediating breast cancer metastasis to bone.
    Cancer Cell. 2003 Jun;3(6):537-49 PMID: 12842083
  47. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma.
    Genes Chromosomes Cancer. 2002 Sep;35(1):58-65 PMID: 12203790
  48. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
    Ann N Y Acad Sci. 2006 Jul;1070:500-6 PMID: 16888216
  49. Tumor metastasis: mechanistic insights and clinical challenges.
    Nat Med. 2006 Aug;12(8):895-904 PMID: 16892035
  50. Dissemination and growth of cancer cells in metastatic sites.
    Nat Rev Cancer. 2002 Aug;2(8):563-72 PMID: 12154349
  51. KISS1 metastasis suppression and emergent pathways.
    Clin Exp Metastasis. 2003;20(1):11-8 PMID: 12650602
  52. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
    J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92 PMID: 16954471
  53. Molecular signature associated with bone marrow micrometastasis in human breast cancer.
    Cancer Res. 2003 Sep 15;63(18):5679-84 PMID: 14522883
  54. A gene-expression signature as a predictor of survival in breast cancer.
    N Engl J Med. 2002 Dec 19;347(25):1999-2009 PMID: 12490681
  55. Cancer epigenomics: DNA methylomes and histone-modification maps.
    Nat Rev Genet. 2007 Apr;8(4):286-98 PMID: 17339880
  56. High sensitivity mapping of methylated cytosines.
    Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 PMID: 8065911
  57. Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene-treated MCF7 breast cancer cells.
    J Biol Chem. 2008 Feb 15;283(7):4051-60 PMID: 18065415
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
Published
2008-00-00
Epub
2008-00-18
Pages
R62
Language
English
Region
England
NLM ID
100927353
PMCID
PMC2575535
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com